About Event
The Stanford Cancer Institute was thrilled to host members of our Cancer Cell Biology and Cancer Therapeutic programs for a half-day symposium on May 7, 2026, exploring the translation of basic science discoveries into life-changing cancer treatments.
The symposium’s sessions focused on:
-
Sharing success stories of how basic science discoveries are being translated into experimental therapeutics through collaborative research.
-
Providing a platform for investigators to pitch the translational potential of their basic science research, opening the door for future interactions and collaborations.
- Agenda
- Speakers
- Event Organizers
- Registration
- Travel Information
- FAQ's
12:30 - 1:00 p.m.
Registration
1:00 - 1:05 p.m.
Introduction and Overview
Steven Artandi, MD, PhD, Laurie Kraus Lacob Director, Stanford Cancer Institute
Chief Cancer Officer, Stanford Medicine - Health Care
Senior Associate Dean for Cancer Programs, Stanford Medicine
Jerome and Daisy Low Gilbert Professor of Medicine and Biochemistry
Nathanael Gray, PhD, Krishnan-Shah Family Professor of Chemical and Systems Biology
Co-Leader of the Cancer Therapeutics Program, Stanford Cancer Institute
Laura Attardi, PhD, Catharine and Howard Avery Professor of the School of Medicine and Professor of Genetics
Co-Leader of the Cancer Cell Biology Program, Stanford Cancer Institute
Session I
1:05 - 1:25 p.m.
ENPP1 Immune Checkpoint Blockade for Breast Cancer Treatment
Lingyin Li, PhD, Professor of Biochemistry
1:25 - 1:45 p.m.
Chemical Interrogation and Targeting ALDH1B1-dependent Tumor Growth
James Chen, PhD, Jauch Professor and Professor of Chemical and Systems Biology, of Developmental Biology and of Chemistry
1:45 - 2:05 p.m.
Subcellular Transcriptomics Reveals CTSW as a Regulator of CAR T Cell Persistence and a Target for Cancer Immunotherapy
Rogelio Hernández-López, PhD, Assistant Professor of Bioengineering and of Genetics
2:05 - 2:25 p.m.
Scaling Discovery Across Molecular and Genetic Space
Steven Banik, PhD, Assistant Professor of Chemistry
2:25 - 2:45 p.m.
A Multi-agent AI Platform for Accurately Determining Drug Mechanism-of-action at Scale
Jason Sheltzer, PhD, Assistant Professor of Radiation Oncology (Radiation and Cancer Biology)
2:45 - 3:15 p.m.
Coffee Break
Session II
3:15 - 3:35 p.m.
Discovery of TRIM21 Molecular Glues that Drive Potent Anti-tumor Efficacy via Nuclear Pore Complex Degradation
Steven Corsello, MD, Assistant Professor of Medicine (Oncology) and, by courtesy, of Chemical and Systems Biology
3:35 - 3:55 p.m.
Discovery of Genotype-specific Therapeutic Targets Using Autochthonous Cancer Models
Monte Winslow, PhD, Associate Professor of Genetics and of Pathology
Dmitri Petrov, PhD, Michelle and Kevin Douglas Professor in the School of Humanities and Sciences
3:55 - 4:15 p.m.
How to Restart Stalled Replication Forks During Replication Stress
Gheorghe Chistol, PhD, Assistant Professor of Chemical and Systems Biology
4:15 - 4:35 p.m.
Drugging the Undruggable: Toward Targeting the P53 Pathway
Laura Attardi, PhD, Catharine and Howard Avery Professor of the School of Medicine and Professor of Genetics
Xijun Zhu, Graduate Student in Chemistry, Gray Lab
4:35 - 5:15 p.m.
Panel Discussion
Nathanael Gray, PhD, Krishnan-Shah Family Professor of Chemical and Systems Biology (Moderator)
Laura Attardi, PhD, Catharine and Howard Avery Professor of the School of Medicine and Professor of Genetics
Peter Jackson, PhD, Professor of Microbiology and Immunology (Baxter Labs) and of Pathology
Crystal Mackall, MD, Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Caitlyn Miller, PhD, CEO and Co-Founder of TwoStep Therapeutics
Irving Weissman, MD, Virginia & D.K. Ludwig Professor of Clinical Investigation in Cancer Research, Professor of Pathology, and of Developmental Biology
5:15 p.m.
Closing Remarks
